SA
BMRN icon

SpiderRock Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

SpiderRock Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Hold
0
– -$11K – 905
2017
Q1 		– Hold
0
– – – 789

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

SpiderRock Advisors's BMRN Position: Q3 2024 in Review

SpiderRock Advisors held its BioMarin Pharmaceuticals (BMRN) position steady in Q3 2024 at 5,815 shares worth $409K. The position accounts for 0.01% of the portfolio, ranked #667.

SpiderRock Advisors first reported a position in BMRN in Q1 2024 and has held it in 3 quarters since. The position peaked at $487K in Q1 2024. 553 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

  • SpiderRock Advisors held 5,815 shares of BioMarin Pharmaceuticals worth $409K as of Q3 2024.
  • SpiderRock Advisors left its BioMarin Pharmaceuticals share count unchanged in Q3 2024.
  • BioMarin Pharmaceuticals made up 0.01% of SpiderRock Advisors's portfolio in Q3 2024, its #667 holding.
  • SpiderRock Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2024 and has held it in 3 quarters since.
  • SpiderRock Advisors's BioMarin Pharmaceuticals position peaked at $487K in Q1 2024.
  • 553 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on SpiderRock Advisors's 13F filing for Q3 2024, filed 1 Nov 2024.